Stefan Winter

Stefan Winter

Auto-generated profile, based on publicly available information

Stefan Winter

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
Kathrin KleinKathrin Klein
Kathrin Klein
Roman TremmelRoman Tremmel
Roman Tremmel
SWStefan Winter
Stefan Winter
SFSarah Fehr
Sarah Fehr
FBFlorian Battke
Florian Battke
UZUlrich M. Zanger
Ulrich M. Zanger
We developed a panel-based NGS pipeline for comprehensive analysis of 340 genes involved in absorption, distribution, metabolism and excretion (ADME) of drugs, other xenobiotics, and endogenous substances. The 340 genes comprised phase I and II enzymes, drug transporters and regulator/modifier genes within their entire coding regions, adjacent intron regions and 5′ and 3′UTR regions, resulting in a total panel size of 1,382 kbp. We applied the ADME NGS panel to sequence genomic DNA from 150 Caucasian liver donors with available comprehensive gene expression data. This revealed an average read-depth of 343 (range 27–811), while 99% of the 340 genes were covered on average at least 100-fold. Direct comparison of variant annotation with 363 available genotypes determined independently by other methods revealed an overall accuracy of >99%. Of 15,727 SNV and small INDEL variants, 12,022 had a minor allele frequency (MAF) below 2%, including 8,937 singletons. In total we found 7,273 novel variants. Functional predictions were computed for coding variants (n = 4,017) by three algorithms (Polyphen 2, Provean, and SIFT), resulting in 1,466 variants (36.5%) concordantly predicted to be damaging, while 1,019 variants (25.4%) were predicted to be tolerable. In agreement with other studies we found that less common variants were enriched for deleterious variants. Cis-eQTL analysis of variants with (MAF ≥ 2%) revealed significant associations for 90 variants in 31 genes after Bonferroni correction, most of which were located in non-coding regions. For less common variants (MAF < 2%), we applied the SKAT-O test and identified significant associations to gene expression for ADH1C and GSTO1. Moreover, our data allow comparison of functional predictions with additional phenotypic data to prioritize variants for further analysis.

9 December 2015 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
Werner SchrothWerner Schroth
Werner Schroth
SWS. Winter
S. Winter
FBF. Büttner
F. Büttner
SGS. Goletz
S. Goletz
SFS. Faißt
S. Faißt
PFP. Fritz
P. Fritz

28 March 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
IHI A Hauser
I A Hauser
SKStephan Kruck
Stephan Kruck
SGS Gauer
S Gauer
ANAnne Nies
Anne Nies
SWS Winter
S Winter
ESE Schaeffeler
E Schaeffeler

27 October 2015 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
Roman TremmelRoman Tremmel
Roman Tremmel
Kathrin KleinKathrin Klein
Kathrin Klein
SWS Winter
S Winter
ESE Schaeffeler
E Schaeffeler
UZU M Zanger
U M Zanger

29 November 2010 in Cancer
Verified
Journal Article
Open access
PDF file
CJChristina Justenhoven
Christina Justenhoven
SWStefan Winter
Stefan Winter
UHUte Hamann
Ute Hamann
SHSusanne Haas
Susanne Haas
HFHans‐Peter Fischer
Hans‐Peter Fischer
FNFor The Genica Network
For The Genica Network
BACKGROUND: CYP3A enzymes, due to their role in the metabolism of steroid hormones, are suggested to affect carcinogenesis of hormone‐related cancers. The purpose of the present study was to evaluate the association between polymorphisms located in CYP3A43, breast cancer risk, and tumor characteristics.METHODS: A 3‐plex matrix‐assisted laser desorption ionization time of flight mass spectrometry assay has been established for CYP3A43_74_delA (CYP3A43*2A), CYP3A43_1018_C>G (CYP3A43*3), and CYP3A43_1047_C>T (CYP3A43*1B) polymorphisms, and 1021 breast cancer cases and 1015 age‐matched, population‐based controls from the German GENICA collection have been genotyped.RESULTS: No differences in genotype frequencies between cases and controls were observed, indicating that CYP3A43_74_delA is not associated with breast cancer risk. Subgroup analyses showed an association between the CYP3A43_74_delA allele and high‐grade tumors (odds ratio, 1.74; 95% confidence interval, 1.14‐2.65 [P = .010 and Ptrend = .012]).CONCLUSIONS: The data support the notion that the CYP3A43_74_delA variant may result in decreased protein and/or activity levels, and this may further lead to increased hormone levels to promote tumor cell growth and hinder differentiation. Cancer 2010. © 2010 American Cancer Society.

24 December 2018 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
ELE Lebedeva
E Lebedeva
AGA Gorokhov
A Gorokhov
ESE Schastnyy
E Schastnyy
ARA Repin
A Repin
GSGerman Simutkin
German Simutkin
NBNikolay A. Bokhan
Nikolay A. Bokhan
Динамика когнитивной дисфункции и биохимического маркера повреждения ЦНС S100ß при коронарном шунтировании